Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | SERPINA3 | P01011 | 1/20 | 0.35 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17712309 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9SERPINA3ADCY2 | |
| SCHEMBL22342700 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9SERPINA3ADCY2 | |
| SCHEMBL22342703 | 0.94 | TMPRSS2 (0.41) | TMPRSS2CYP3A4CYP2C9RIPK1 | |
| SCHEMBL30001635 | 0.94 | TMPRSS2 (0.41) | TMPRSS2CYP3A4CYP2C9RIPK1 | |
| SCHEMBL21342879 | 0.94 | TMPRSS2 (0.41) | TMPRSS2CYP3A4CYP2C9RIPK1 | |
| SCHEMBL17719236 | 0.94 | TMPRSS2 (0.41) | TMPRSS2CYP3A4CYP2C9RIPK1 | |
| SCHEMBL25246889 | 0.92 | TMPRSS2 (0.42) | TMPRSS2RIPK1 | |
| SCHEMBL20477146 | 0.92 | TMPRSS2 (0.42) | TMPRSS2RIPK1 | |
| SCHEMBL17712284 | 0.92 | TMPRSS2 (0.42) | TMPRSS2RIPK1 | |
| SCHEMBL30939856 | 0.92 | TMPRSS2 (0.42) | TMPRSS2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4591935-A2 | METHODS FOR THE PREPARATION OF RIBOSIDES | Gilead Sciences, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4588928-A2 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4036099-B1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | GILEAD SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230027727-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4096678-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-4088718-A1 | METHODS FOR TREATING CORONAVIRIDAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20220354873-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2022-11-10 | — | — | US | disclosed |
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3212175-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | Gilead Sciences, Inc. (US) | 2017-09-06 | — | — | EP | disclosed |
| US-9724360-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| WO-2017049060-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| WO-2016069825-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016069827-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | PRPS1, PRPF4, PRPF31 | TMPRSS2 3100/4885CYP3A4 2895/4885CYP2C9 4593/4885 |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | TMPRSS2 1951/4885CYP3A4 772/4885CYP2C9 2974/4885 |
| US-20220354873-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | PRPS1, PRPF4, PRPF31 | TMPRSS2 3100/4885CYP3A4 2895/4885CYP2C9 4593/4885 |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | ACE2, ACE, PNP | TMPRSS2 6/4885CYP3A4 296/4885CYP2C9 476/4885 |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | TMPRSS2 12/4885CYP3A4 1145/4885CYP2C9 2167/4885 |
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | ACE2, ACE, PNP | TMPRSS2 6/4885CYP3A4 296/4885CYP2C9 476/4885 |
| US-20230027727-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | PNP, ACE, ACE2 | TMPRSS2 14/4885CYP3A4 1181/4885CYP2C9 2188/4885 |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | TMPRSS2 1951/4885CYP3A4 772/4885CYP2C9 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.